Global Anti- Tuberculosis Drugs Market - Growth, Trends and Forecast 2017 - 2022

  • ID: 4388391
  • Report
  • Region: Global
  • 205 pages
  • Mordor Intelligence
1 of 3
The Global market for Anti-Tuberculosis drugs Market is expected to reach $XX by the end of 2020 growing at a CAGR of around XX% from 2015 to 2021. Tuberculosis is amongst one of the most deadly communicable disease. It is the second most leading cause of death from a single infectious agent after HIV. It is caused by different strains of Mycobacterium. According to WHO 2014 report, in 2013, approximately around 9.0 million people developed TB and 1.5 million deaths were recorded. Amongst these, 360000 patients were found to be HIV- positive. China and India are amongst the most affected countries which account 24% and 11% of cases, respectively. However, there is a decline in patient population every year. On the other hand, there is a growth in Multi drug resistant tuberculosis.

The market for anti-Tuberculosis drugs have been segmented based on the therapeutic efficacy i.e. First line drugs, Second line drugs, and Combination therapy. Market for the Anti-Tuberculosis drugs is dependent on the therapeutic efficacy of the drug. There is a growing problem of Multi Drug resistant Tuberculosis (MDR-TB), so, market for exclusive MDR-TB drugs is expected to increase along with Combination therapy. However, there is a yearly decline in patient pool, so, a market decline in Standalone first line or second line drugs is expected. Communicable nature, Drug resistance and HIV-TB co-infection will be market drivers for new entrants. Rifampicin, Isoniazide, Ethambutol, Pyrazinamide are amongst the most widely prescribed drugs. Flouroquinolones and newer drugs are successful in improving the condition for MDR-TB, so the market for the same is expected to increase. China, India, Pakistan, and other Asian and African countries are majorly affected and most patient pool lies in these region. Key Players in tuberculosis drugs market are Astrazeneca, Lupin, Alkem Laboratories, Novartis, Merck, Zydus cadilia and others.

Drivers

Growing problem of MDR-TB, Deadly and contagiousness/ communicable nature of the disease are the major market drivers. Along with these, Tuberculosis -HIV co-infection and not much availability to treat the same will be a market driver for Research and Development companies aspiring to launch better product. Overall, there is a need for newer drugs for treatment of Tuberculosis.

Challenges

High expenditure of on research and development, Drug resistant tuberculosis, extreme difficulty in R&D for HIV - TB co-infection pose challenge in Market for anti-obesity drugs.

This Report Offers:

1) Market Definition for the specified topic along with identification of key drivers and restraints for the market.

2) Market analysis for the Global Anti-Tuberculosis drugs Market, with region specific assessments and competition analysis on a global and regional scale.

3) Identification of factors instrumental in changing the market scenarios, rising prospective opportunities and identification of key companies which can influence the market on a global and regional scale.

4) Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market shares

5) Identification and analysis of the Macro and Micro factors that affect the Anti-Tuberculosis drugs Market on both global and regional scale.

6) A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Introduction
1.1 Report Description
1.2 Research Methodology
2. Executive Summary
3. Market Overview
3.1 Market Definition
3.2 Market Drivers
3.2.1 Innovative technologies
3.2.2 Incidence of diseases
3.2.3 Increasing stem cell banking services
3.2.4 Awareness among public
3.2.5 Other factors
3.3 Market restraints
3.3.1 High operational cost
3.3.2 Regulatory factors
4. Porters Five Force Analysis
4.1 Bargaining Power of suppliers
4.2 Bargaining power of buyers
4.3 Degree of competition
4.4 Threat of substitution
4.5 Threat of new entrants
5. Market Segmentation
5.1 By Products
5.1.1 Adult stem cells
5.1.1.1 Umbilical cord stem cells
5.1.1..2 Dental stem cells
5.1.1.3 Neuronal stem cells
5.1.1.4 Mesenchymal stem cells
5.1.1.5 Hematopoietic stem cells
5.1.2 Embryonic stem cells
5.1.3 Induced pluripotent stem cells
5.2 By Technology
5.2.1 Culturing
5.2.2 Isolation
5.2.3 In-vitro fertilization
5.2.4 Cryopreservation
5.2.5 Expansion
5.3 By Application
5.3.1 Neurology
5.3.2 Orthopedics
5.3.3 Oncology
5.3.4 Hematology
5.3.5 Cardiovascular medicine
5.3.6 Diabetes
5.3.7 Liver disorders
5.3.8 Other diseases
5.3.9 Drug Discovery & Development
5.3.10 Regenerative medicine
5.4 By Geography
5.4.1 North America
5.4.1.1 US
5.4.1.2 Canada
5.4.2 Europe
5.4.2.0 France
5.4.2.1 UK
5.4.2.2 Germany
5.4.2.3 Scandinavian Regions
5.4.2.4 Italy
5.4.2.5 Rest of Europe
5.4.3 Asia-Pacific
5.4.3..1 India
5.4.3..2 China
5.4.3..3 Japan
5.4.3..4 Singapore
5.4.4 Rest of the World
6. Competitive Landscape
7. Company Profiles
7.1 Esperite
7.2 NeoStem
7.3 Smart Cells International
7.4 StemCyte
7.5 ViaCord
7.6 Aldagen
7.7 Arteriocyte
7.8 Brainstorm Cell Therapeutics
7.9 Celgene Corporation Inc.
7.10 NovaCord
8. Appendix
8.1 Abbrevations
8.3 Bibliography
8.4 Disclaimer
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll